Loading...
XNASPAHC
Market cap812mUSD
Jan 10, Last price  
20.05USD
1D
-6.66%
1Q
-14.64%
Jan 2017
-31.57%
IPO
20.28%
Name

PHIBRO ANIMAL HEALTH CORP

Chart & Performance

D1W1MN
XNAS:PAHC chart
P/E
336.13
P/S
0.80
EPS
0.06
Div Yield, %
2.39%
Shrs. gr., 5y
Rev. gr., 5y
4.21%
Revenues
1.02b
+4.07%
364,400,000398,400,000453,000,000511,400,000537,100,000594,200,000618,333,000654,101,000653,151,000691,900,000748,591,000751,500,000764,300,000820,000,000828,000,000800,400,000833,400,000942,300,000977,889,0001,017,679,000
Net income
2m
-92.59%
-22,100,000-13,100,000-6,700,0002,200,000-8,300,00042,100,000-12,922,0006,976,00024,891,000-3,100,00060,280,00082,700,00064,600,00064,900,00054,700,00033,552,00054,385,00049,175,00032,606,0002,416,000
CFO
88m
+558.11%
-4,750,00034,660,0002,860,000-6,160,000810,000-4,730,000-4,680,00031,988,000415,000-712,00068,704,00037,218,00098,400,00070,008,00047,169,00059,348,00048,306,00031,649,00013,310,00087,594,000
Dividend
Sep 04, 20240.12 USD/sh
Earnings
Feb 05, 2025

Profile

Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
IPO date
Apr 11, 2014
Employees
1,920
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
1,017,679
4.07%
977,889
3.78%
942,300
13.07%
Cost of revenue
733,781
704,047
677,732
Unusual Expense (Income)
NOPBT
283,898
273,842
264,568
NOPBT Margin
27.90%
28.00%
28.08%
Operating Taxes
8,500
21,465
23,200
Tax Rate
2.99%
7.84%
8.77%
NOPAT
275,398
252,377
241,368
Net income
2,416
-92.59%
32,606
-33.69%
49,175
-9.58%
Dividends
(19,442)
(19,442)
(19,442)
Dividend yield
2.86%
3.50%
2.51%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
37,255
33,117
21,051
Long-term debt
525,579
516,748
486,992
Deferred revenue
13,048
Other long-term liabilities
18,973
19,124
19,728
Net debt
436,733
457,490
406,449
Cash flow
Cash from operating activities
87,594
13,310
31,649
CAPEX
(41,238)
(51,794)
(37,044)
Cash from investing activities
(48,194)
(74,018)
(22,582)
Cash from financing activities
(6,768)
26,987
16,343
FCF
261,612
214,141
178,237
Balance
Cash
114,613
81,281
91,248
Long term investments
11,488
11,094
10,346
Excess cash
75,217
43,481
54,479
Stockholders' equity
120,363
146,706
126,639
Invested Capital
722,925
717,947
690,964
ROIC
38.23%
35.83%
36.86%
ROCE
34.95%
35.40%
35.06%
EV
Common stock shares outstanding
40,523
40,504
40,504
Price
16.77
22.41%
13.70
-28.38%
19.13
-33.76%
Market cap
679,571
22.47%
554,905
-28.38%
774,842
-33.76%
EV
1,116,304
1,012,395
1,181,291
EBITDA
320,076
307,854
297,273
EV/EBITDA
3.49
3.29
3.97
Interest
21,970
17,949
11,900
Interest/NOPBT
7.74%
6.55%
4.50%